Canopy Growth (CGC) Q1 2027 earnings review
Growth Accelerates, But Cash Burn Resurfaces
Canopy Growth delivered an encouraging 13% YoY revenue jump to $81.2M, firing on all cylinders across its business units. The integration of MTL Cannabis is already paying off, driving a 22% surge in Canada medical sales and a 10% lift in adult-use. Meanwhile, the Storz & Bickel vaporizer segment finally reversed its slump, showing 6% growth and a massive margin expansion. Adjusted EBITDA loss remained stable at $3.2M. However, underneath the improved top line, Free Cash Flow burn doubled year-over-year, largely due to working capital demands. Canopy is closer to profitability than it has been in years, but it still needs to prove it can grow without draining its cash reserves.
🐂 Bull Case
Every single business segment posted top-line growth. The MTL Cannabis acquisition is delivering high-quality flower that translates directly into market share gains in Canada.
After struggling with soft consumer demand last year, the vaporizer unit reversed its slide. Cost rationalization drove S&B gross margins from 29% to a stellar 48%.
🐻 Bear Case
Free cash outflow hit $25.7M, more than double the $11.6M burn from a year ago. If working capital timing issues persist, the balance sheet could come under pressure again.
Canada's medical segment grew volumes, but adjusted gross margins were weighed down by a government-mandated reduction in the Veterans Affairs Canada (VAC) reimbursement rate.
⚖️ Verdict: ⚪
Neutral. The top-line acceleration and MTL integration are clear operational wins, but the widening cash burn and regulatory pricing pressures keep the overall picture mixed.
Key Themes
MTL Cannabis Acquisition Fueling Growth
The MTL Cannabis integration is proving to be a potent catalyst, accelerating sales across Canadian markets. Canada Medical revenue jumped 22% YoY, and Adult-Use grew 10%. Management specifically pointed to increased high-quality flower supply and expanded brand offerings (like Claybourne's new Frosted Flyers) as primary growth engines.
Storz & Bickel Margins Reverse Upward
Storz & Bickel reversed its historical weakness, expanding gross margins dramatically from 29% in 26Q1 to 48% this quarter. This was driven by aggressive cost rationalization initiated late last year and the recovery of certain U.S. tariffs. Revenue also returned to growth, increasing 6% YoY to $16.1M.
Free Cash Flow Deterioration
Free cash flow trend is decelerating sharply. Outflow increased from $11.6M in 26Q1 to $25.7M in 27Q1. While management attributes this to the timing of working capital items, it contradicts the positive narrative of the company reaching near-breakeven Adjusted EBITDA (-$3.2M). Cash burn must be monitored closely.
VAC Reimbursement Rate Cut
The Canadian government's reduction in the Veterans Affairs Canada (VAC) reimbursement rate for medical cannabis represents a structural headwind. While medical volume increased 22%, the lower pricing cap dragged down the adjusted gross margin for the entire Cannabis segment, partially offsetting the benefits of top-line growth.
Accounting Charges Masking Margin Gains
Reported Cannabis gross margin actually fell to 22% from 24% YoY. This was caused by $2.6M in inventory step-up charges tied to the MTL Cannabis acquisition. Once adjusted, the underlying Cannabis gross margin expanded from 24% to 26%, but investors need to look through these accounting artifacts to see the real operational leverage.
Other KPIs
SG&A expenses were 6% higher than last year. The addition of MTL Cannabis operations drove costs up, though this was largely offset by continued reductions in headcount and other structural cost savings implemented over the past year.
Down slightly from $364.7M at the end of FY26 (March 31), but still provides Canopy with a highly defensive balance sheet to absorb near-term FCF burn while funding ongoing integration efforts.
Accelerating slightly, up 10% YoY. Growth was primarily led by strength in Europe, specifically Poland, validating the company's shift toward supplying international demand with premium Canadian flower.
Guidance
Stable to Accelerating. The company did not provide specific quantitative guidance for the upcoming quarter, but stated they anticipate further improvements in financial results, especially in the second half of fiscal 2027 as the MTL Cannabis integration is fully completed.
Key Questions
Working Capital Reversal
Free cash flow burn more than doubled this quarter to $25.7M, which you attributed to working capital timing. When specifically do you expect these working capital investments to convert back to cash?
VAC Reimbursement Impact
Can you quantify the exact margin drag caused by the VAC reimbursement rate reduction in Q1, and are there further mitigation strategies planned beyond standard volume growth?
Storz & Bickel Tariffs
S&B gross margins benefited significantly from the recovery of certain U.S. tariffs. How much of the 48% margin was a one-time benefit, and what is a normalized run-rate margin for this segment going forward?
MTL Synergies Timeline
You noted expected financial improvements in the second half of the year as the MTL integration is completed. What specific operational synergies are still left to unlock over the next two quarters?